The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity
Open accessAbstract
Widely used as anticancer and immunosuppressive agents, thiopurines have narrow therapeutic indices owing to frequent toxicities, partly explained by TPMT genetic polymorphisms. Recent studies identified germline NUDT15 variation as another critical determinant of thiopurine intolerance, but the underlying molecular mechanisms and the clinical implications of this pharmacogenetic association remain unknown. In 270 children enrolled in clinical trials for acute lymphoblastic leukemia in Guatemala, Singapore and Japan, we identified four NUDT15 coding variants (p.Arg139Cys, p.Arg139His, p.Val18Ile and p.Val18_Val19insGlyVal) that resulted in 74.4–100% loss of nucleotide diphosphatase activity. Loss-of-function NUDT15 diplotypes were consistently associated with thiopurine intolerance across the three cohorts (P = 0.021, 2.1 × 10−5 and 0.0054, respectively; meta-analysis P = 4.45 × 10−8, allelic effect size = −11.5). Mechanistically, NUDT15 inactivated thiopurine metabolites and decreased thiopurine cytotoxicity in vitro, and patients with defective NUDT15 alleles showed excessive levels of thiopurine active metabolites and toxicity. Taken together, these results indicate that a comprehensive pharmacogenetic model integrating NUDT15 variants may inform personalized thiopurine therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Statistical Method for Haplotype Reconstruction from Population Data
Stephens, M., Smith, N. J., & Donnelly, P. (2001) · The American Journal of Human Genetics · doi:10.1086/319501 · Cited by 7,493
A Re-Evaluation of Random-Effects Meta-Analysis
Higgins, J. P. T., Thompson, S. G., & Spiegelhalter, D. J. (2009) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2008.00552.x · Cited by 2,569
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
Jordheim, L. P., Durantel, D., Zoulim, F., & Dumontet, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4010 · Cited by 1,211
Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
Pui, C.-H., Carroll, W. L., Meshinchi, S., & Arceci, R. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7405 · Cited by 842
Self-citationYates, C. R., Krynetski, E. Y., Loennechen, T., Fessing, M. Y., Tai, H.-L., Pui, C.-H., Relling, M. V., & Evans, W. E. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-8-199704150-00003 · Cited by 756
Self-citationRelling, M. V., Hancock, M. L., Rivera, G. K., Sandlund, J. T., Ribeiro, R. C., Krynetski, E. Y., Pui, C.-H., & Evans, W. E. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.23.2001 · Cited by 733
Self-citationThe purine path to chemotherapy
Elion, G. B. (1989) · Science · doi:10.1126/science.2649979 · Cited by 687
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
Lennard, L., Lilleyman, J. S., Van Loon, J., & Weinshilboum, R. M. (1990) · The Lancet · doi:10.1016/0140-6736(90)91745-v · Cited by 651
Holleman, A., Cheok, M. H., den Boer, M. L., Yang, W., Veerman, A. J. P., Kazemier, K. M., Pei, D., Cheng, C., Pui, C.-H., Relling, M. V., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033513 · Cited by 633
Self-citationThe efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review
Fraser, A. G. (2002) · Gut · doi:10.1136/gut.50.4.485 · Cited by 629
Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C.-H., Yee, S. W., Stein, C. M., Carrillo, M., Evans, W. E., & Klein, T. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.320 · Cited by 574
Self-citationA controlled double blind study of azathioprine in the management of Crohn's disease.
Candy, S., Wright, J., Gerber, M., Adams, G., Gerig, M., & Goodman, R. (1995) · Gut · doi:10.1136/gut.37.5.674 · Cited by 567
A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia
Yang, S.-K., Hong, M., Baek, J., Choi, H., Zhao, W., Jung, Y., Haritunians, T., Ye, B. D., Kim, K.-J., Park, S. H., et al. (2014) · Nature Genetics · doi:10.1038/ng.3060 · Cited by 549
Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.
Connell, W. R., Kamm, M. A., Ritchie, J. K., & Lennard-Jones, J. E. (1993) · Gut · doi:10.1136/gut.34.8.1081 · Cited by 510
Vora, A., Goulden, N., Wade, R., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., & Richards, S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70600-9 · Cited by 478
Karran, P., & Attard, N. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2292 · Cited by 477
Hanauer, S. B., Korelitz, B. I., Rutgeerts, P., Peppercorn, M. A., Thisted, R. A., Cohen, R. D., & Present, D. H. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.06.002 · Cited by 460
Yang, J. J., Landier, W., Yang, W., Liu, C., Hageman, L., Cheng, C., Pei, D., Chen, Y., Crews, K. R., Kornegay, N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4671 · Cited by 445
Self-citationRole of Postreplicative DNA Mismatch Repair in the Cytotoxic Action of Thioguanine
Swann, P. F., Waters, T. R., Moulton, D. C., Xu, Y.-Z., Zheng, Q., Edwards, M., & Mace, R. (1996) · Science · doi:10.1126/science.273.5278.1109 · Cited by 408
Evans, W. E., Hon, Y. Y., Bomgaars, L., Coutre, S., Holdsworth, M., Janco, R., Kalwinsky, D., Keller, F., Khatib, Z., Margolin, J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2293 · Cited by 400
Self-citationPrognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia
Relling, M. V., Hancock, M. L., Boyett, J. M., Pui, C.-H., & Evans, W. E. (1999) · Blood · doi:10.1182/blood.v93.9.2817 · Cited by 395
Self-citationActivating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL
Tzoneva, G., Perez-Garcia, A., Carpenter, Z., Khiabanian, H., Tosello, V., Allegretta, M., Paietta, E., Racevskis, J., Rowe, J. M., Tallman, M. S., et al. (2013) · Nature Medicine · doi:10.1038/nm.3078 · Cited by 350
Krynetski, E. Y., Schuetz, J. D., Galpin, A. J., Pui, C. H., Relling, M. V., & Evans, W. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.4.949 · Cited by 306
Self-citationRelapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia
Meyer, J. A., Wang, J., Hogan, L. E., Yang, J. J., Dandekar, S., Patel, J. P., Tang, Z., Zumbo, P., Li, S., Zavadil, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2558 · Cited by 297
Self-citationAzathioprine: old drug, new actions
Maltzman, J. S., & Koretzky, G. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18384 · Cited by 268
Tai, H.-L., Krynetski, E. Y., Schuetz, E. G., Yanishevski, Y., & Evans, W. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6444 · Cited by 259
Self-citationSchwab, M. G., Schäffeler, E., Marx, C., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00003 · Cited by 258
Self-citationVariable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia.
Lennard, L., & Lilleyman, J. S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.12.1816 · Cited by 244
Schmiegelow, K., Nielsen, S. N., Frandsen, T. L., & Nersting, J. (2014) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000206 · Cited by 239
Self-citationReinisch, W., Angelberger, S., Petritsch, W., Shonova, O., Lukas, M., Bar-Meir, S., Teml, A., Schaeffeler, E., Schwab, M., Dilger, K., et al. (2010) · Gut · doi:10.1136/gut.2009.194159 · Cited by 172
Self-citationHINDORF, U., LINDQVIST, M., HILDEBRAND, H., FAGERBERG, U., & ALMER, S. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02977.x · Cited by 168
Teml, A., Schaeffeler, E., Herrlinger, K. R., Klotz, U., & Schwab, M. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746030-00001 · Cited by 159
Self-citationSystemic Exposure to Mercaptopurine as a Prognostic Factor in Acute Lymphocytic Leukemia in Children
Koren, G., Ferrazzini, G., Sulh, H., Langevin, A. M., Kapelushnik, J., Klein, J., Giesbrecht, E., Soldin, S. J., & Greenberg, M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007053230104 · Cited by 138
Yeoh, A. E. J., Ariffin, H., Chai, E. L. L., Kwok, C. S. N., Chan, Y. H., Kuperan, P., Campana, D., Tan, P. L., Chan, M. Y., Kham, S. K. Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5936 · Cited by 135
Self-citationThiopurine methyltransferase in acute lymphoblastic leukemia
Relling, M. V., Pui, C., Cheng, C., & Evans, W. E. (2006) · Blood · doi:10.1182/blood-2005-08-3379 · Cited by 131
Self-citationDiouf, B., Cheng, Q., Krynetskaia, N. F., Yang, W., Cheok, M., Pei, D., Fan, Y., Cheng, C., Krynetskiy, E. Y., Geng, H., et al. (2011) · Nature Medicine · doi:10.1038/nm.2430 · Cited by 129
Self-citationDrug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD
de Boer, N. K. H., Bodegraven, A. A. V., Jharap, B., de Graaf, P., & Mulder, C. J. J. (2007) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep1000 · Cited by 128
Schmiegelow, K., Forestier, E., Kristinsson, J., Söderhäll, S., Vettenranta, K. K., Weinshilboum, R. M., Wesenberg, F., & On behalf of the Nordic Society of Paediatric Haematology and Oncology (NOPHO) (2008) · Leukemia · doi:10.1038/leu.2008.316 · Cited by 122
Self-citationCarter, M., Jemth, A., Hagenkort, A., Page, B. D. G., Gustafsson, R., Griese, J. J., Gad, H., Valerie, N. C. K., Desroses, M., Boström, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms8871 · Cited by 118
Krynetski, E. Y., Krynetskaia, N. F., Bianchi, M. E., & Evans, W. E. (2003) · PubMed · Cited by 108
Self-citationHuman MTH3 (NUDT18) Protein Hydrolyzes Oxidized Forms of Guanosine and Deoxyguanosine Diphosphates
Takagi, Y., Setoyama, D., Ito, R., Kamiya, H., Yamagata, Y., & Sekiguchi, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.363010 · Cited by 105
Posthuma, E. F. M., Westendorp, R. G. J., Veer, A. V. D. S., Kluin‐Nelemans, H. C., Kluin, P. M., & Lamers, C. B. H. W. (1995) · Gut · doi:10.1136/gut.36.2.311 · Cited by 93
Xu, H. Y., Zhang, H., Yang, W., Yadav, R., Morrison, A. C., Qian, M., Devidas, M., Liu, Y., Pérez-Andreu, V., Zhao, X., et al. (2015) · Nature Communications · doi:10.1038/ncomms8553 · Cited by 82
Self-citationTIDD, D. M., & Paterson, A. R. P. (1974) · PubMed · Cited by 79
Thiopurines: Factors influencing toxicity and response
Fotoohi, A. K., Coulthard, S. A., & Albertioni, F. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.006 · Cited by 74
Hofmann, U., Heinkele, G., Angelberger, S., Schaeffeler, E., Lichtenberger, C., Jaeger, S. U., Reinisch, W., & Schwab, M. G. (2012) · Analytical Chemistry · doi:10.1021/ac2031699 · Cited by 63
Self-citationJacobsen, J. H., Schmiegelow, K., & Nersting, J. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.11.032 · Cited by 62
Self-citationRegueiro, M., & Mardini, H. E. (2002) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200209000-00008 · Cited by 58
Kham, S. K. Y., Soh, C. K., Liu, T. C., Chan, Y. H., Ariffin, H., Tan, P. L., & Yeoh, A. E. J. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0426-x · Cited by 55
Self-citationToxicity and response to thiopurines in patients with inflammatory bowel disease
Goldberg, R., & Irving, P. M. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1039987 · Cited by 46
Sørum, M. E., Nersting, J., Jacobsen, J. H., Frandsen, T. L., Vettenranta, K. K., Abrahamsson, J., Wesenberg, F., & Schmiegelow, K. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.81 · Cited by 34
Self-citationThe Human NUDT Family of Nucleotide Hydrolases
McLennan, A. G., CARTWRIGHT, J. L., & Gasmi, L. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46843-3_23 · Cited by 16
Msh2 Deficiency Attenuates But Does Not Abolish Thiopurine Hematopoietic Toxicity in Msh2-- Mice
Krynetskaia, N. F., Brenner, T. L., Krynetski, E. Y., Du, W., Panetta, J. C., Pui, C., & Evans, W. E. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.2.456 · Cited by 12
Self-citation
Cited by
Cancer health disparities in racial/ethnic minorities in the United States
Zavala, V. A., Bracci, P. M., Carethers, J. M., Carvajal-Carmona, L., Coggins, N. B., Cruz-Correa, M. R., Davis, M., de Smith, A. J., Dutil, J., Figueiredo, J. C., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01038-6 · Cited by 912
Self-citationRelling, M. V., Schwab, M., Whirl‐Carrillo, M., Suarez‐Kurtz, G., Pui, C., Stein, C. M., Moyer, A. M., Evans, W. E., Klein, T. E., Antillon‐Klussmann, F. G., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1304 · Cited by 682
Self-citationTreatment and biology of pediatric acute lymphoblastic leukemia
Kato, M., & Manabe, A. (2018) · Pediatrics International · doi:10.1111/ped.13457 · Cited by 261
Self-citationAgrawal, M., Spencer, E. A., Colombel, J.-F., & Ungaro, R. C. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.063 · Cited by 261
Suiter, C. C., Moriyama, T., Matreyek, K. A., Yang, W., Scaletti, E. R., Nishii, R., Yang, W., Hoshitsuki, K., Singh, M., Trehan, A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1915680117 · Cited by 121
Self-citation
Metadata
- Authors
- Moriyama, T., Nishii, R., Perez-Andreu, V., Yang, W., Klussmann, F. A., Zhao, X., Lin, T.-N., Hoshitsuki, K., Nersting, J., Kihira, K., Hofmann, U., Komada, Y., Kato, M., McCorkle, R., Li, L., Koh, K., Najera, C. R., Kham, S. K.-Y., Isobe, T., Chen, Z., Chiew, E. K.-H., Bhojwani, D., Jeffries, C., Lu, Y., Schwab, M., Inaba, H., Pui, C.-H., Relling, M. V., Manabe, A., Hori, H., Schmiegelow, K., Yeoh, A. E. J., Evans, W. E., & Yang, J. J.
- Venue
- Nature Genetics
- Published
- 2016-02-15
- Volume
- 48
- Issue
- 4
- Pages
- 367-373
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2275947820
- Cited by
- 477
- References
- 54
- FWCI
- 58.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.